V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Seagen Executive Compensation (FY22)

SGEN · Executive and director compensation, fiscal 2022 only

The paid brief on Seagen

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): June 1, 2023
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Seagen brief$1,500Get the executive brief
522 figures on this page: 514 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Chief executive, fiscal 2022
◇
David Epstein
Median of the other named officers
$5,830,300
6 officers, excluding the chief executive
Latest say-on-pay support
=
May 31, 2023

More on Seagen

Five data products on this company. Each one is requested through the developer setup page.

Frequently asked questions

Answers drawn from the data on this page.
Who is Seagen's chief executive and what were they paid?
David Epstein, Chief Executive Officer, received $57,460,546 in total compensation for fiscal 2022.
What was Seagen's say-on-pay result?
Shareholders supported the say-on-pay proposal with 54.4% of votes cast for or against in favor at the meeting held May 31, 2023 for fiscal 2022.
Which companies are in Seagen's peer group?
The disclosed peer group includes Alnylam Pharmaceuticals, Inc., BeiGene, Ltd., Biogen Inc., BioMarin Pharmaceutical Inc. and Exact Sciences Corporation, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Epstein
Chief Executive Officer
◇—◇◇——◇◇
Roger Dansey
President, Research and Development and Chief Medical Officer
◇—◇◇◇—◇◇
Clay Siegall
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Jean Liu
Chief Legal Officer
◇—◇—◇—◇◇
Todd Simpson
Chief Financial Officer
◇—◇—◇—◇◇
Chip Romp
Executive Vice President, Commercial U.S.
◇—◇—◇—◇◇
Vaughn Himes
Chief Technical Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Chip R. RompPSU◇◇◇◇◇—◇
Chip R. RompPSU◇◇◇◇◇—◇
Chip R. RompRSU◇——◇——◇
Clay B. SiegallPSU◇◇◇◇◇—◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallRSU◇——◇——◇
Clay B. SiegallPSU◇◇◇◇◇—◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallRSU◇——◇——◇
Clay B. SiegallRSU◇——◇——◇
Clay B. SiegallRSU◇——◇——◇
Clay B. SiegallRSU◇——◇——◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallOPTION◇——◇—◇◇
Clay B. SiegallOPTION◇——◇—◇◇
David R. EpsteinOPTION◇——◇—◇◇
David R. EpsteinRSU◇——◇——◇
David R. EpsteinOPTION◇——◇—◇◇
Jean I. LiuRSU◇——◇——◇
Jean I. LiuRSU◇——◇——◇
Jean I. LiuPSU◇◇◇◇◇—◇
Jean I. LiuPSU◇◇◇◇◇—◇
Roger D. DanseyOPTION◇——◇—◇◇
Roger D. DanseyPSU◇◇◇◇◇—◇
Roger D. DanseyPSU◇◇◇◇◇—◇
Roger D. DanseyPSU◇◇◇◇◇—◇
Roger D. DanseyRSU◇——◇——◇
Todd E. SimpsonPSU◇◇◇◇◇—◇
Todd E. SimpsonRSU◇——◇——◇
Todd E. SimpsonPSU◇◇◇◇◇—◇
Vaughn B. HimesPSU◇◇◇◇◇—◇
Vaughn B. HimesRSU◇——◇——◇
Vaughn B. HimesPSU◇◇◇◇◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Vaughn HimesPSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇8/30/2029
Option◇—◇8/17/2030
Option◇—◇8/16/2031
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Todd SimpsonPSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇8/17/2030
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇8/30/2029
Option◇—◇8/16/2031
RSU◇◇——
PSU◇◇——
RSU◇◇——
Roger DanseyRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇8/16/2031
PSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇8/30/2029
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇8/17/2030
RSU◇◇——
RSU◇◇——
Clay SiegallPSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇8/17/2030
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇8/30/2029
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇8/30/2028
Option◇—◇8/16/2031
RSU◇◇——
Chip RompRSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇8/30/2029
Option◇—◇8/17/2030
Option◇—◇8/16/2031
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Jean LiuPSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇8/30/2029
PSU◇◇——
Option◇—◇8/16/2031
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇8/17/2030
David EpsteinOption◇—◇11/09/2032
RSU◇◇——
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2022
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Felix J. Baker, Ph.D
Board chair
◇◇◇———◇
David W. Gryska
◇◇◇———◇
Nancy A. Simonian, M.D
◇◇◇———◇
Alpna H. Seth, Ph.D
◇◇◇———◇
Ted W. Love, M.D
◇◇◇———◇
Daniel G. Welch
◇◇◇———◇
John A. Orwin
◇◇◇———◇
Sandra M. Swain, M.D
◇◇◇———◇
Marc E. Lippman, M.D
◇—————◇
David R. Epstein served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as RSUs and Options (50/50 split in 2022).
Stock ownership guideline: 5x annual cash retainer for Board service (not including committee retainers)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
  • Alnylam Pharmaceuticals, Inc. ALNY
  • BeiGene, Ltd. symbol not shown
  • Biogen Inc. BIIB
  • BioMarin Pharmaceutical Inc. BMRN
  • Exact Sciences Corporation EXAS
  • Exelixis, Inc. EXEL
  • Horizon Therapeutics plc HZNP
  • Incyte Corporation INCY
  • Jazz Pharmaceuticals plc JAZZ
  • Moderna, Inc. MRNA
  • Neurocrine Biosciences, Inc. NBIX
  • Regeneron Pharmaceuticals, Inc. REGN
  • United Therapeutics Corporation UTHR
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2022May 31, 2023=◇◇◇
2021May 19, 2022=◇◇◇
2020May 19, 2021=◇◇◇
2019May 19, 2020=◇◇◇
2018May 23, 2019=◇◇◇
2017May 18, 2018=◇◇◇
2016May 19, 2017=◇◇◇
2015May 25, 2016=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Seagen files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Seagen disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Seagen sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Seagen recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Seagen's disclosed peer group is defensible, who names Seagen back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
522 figures on this page: 514 cited to the filing that reported them, 8 calculated from figures it prints.
514 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001193125-23-158445
  2. 0001060736-23-000019
    DIRECTOR COMPENSATION · Director Compensation · Grants of Plan-Based Awards in 202 · Outstanding Equity Awards at · and 2 more sections
  3. 0001193125-22-155105
  4. 0001193125-21-166689
  5. 0001193125-20-146223
  6. 0001193125-19-155375
  7. 0001193125-18-168158
  8. 0001193125-17-181719
  9. 0001193125-16-602354
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Seagen executive compensation, FY2022.” https://intel.velarion.ai/comp/SGEN (accessed 2026).
Short form: data: Velarion

The paid brief for Seagen

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Seagen and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Seagen discloses

The companies named in SGEN's own disclosed peer group.

Alnylam Pharmaceuticals, Inc.Biogen Inc.BioMarin Pharmaceutical Inc.Exact Sciences CorporationExelixis, Inc.Horizon Therapeutics plcIncyte CorporationJazz Pharmaceuticals plcModerna, Inc.Neurocrine Biosciences, Inc.Regeneron Pharmaceuticals, Inc.United Therapeutics CorporationVertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy